Evidence map›Paper›PMID 34843474›Full record

ArticlePloS one2021

Peptide vaccines designed with the aid of immunoinformatic against Caseous Lymphadenitis promotes humoral and cellular response induction in mice.

Daniela Droppa-Almeida, Glenda Amaral da Silva, Lívia Maria do Amorim Costa Gaspar, Beatriz Benny Sungaila Pereyra, Roberto José Meyer Nascimento, Sibele Borsuk, Elton Franceschi, Francine Ferreira Padilha

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Bioinformatic Approach of B and T Cell Epitopes of PLD and CP40 Proteins ofInternational journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
  5. Multi-Omics ofProteomes · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniela Droppa-AlmeidaCenter for Studies on Colloidal Systems (NUESC)/Institute of Technology and Research (ITP), Tiradentes University (UNIT), Aracaju, Brazil.ORCID 0000-0002-8154-1030
Glenda Amaral da SilvaCenter for Studies on Colloidal Systems (NUESC)/Institute of Technology and Research (ITP), Tiradentes University (UNIT), Aracaju, Brazil.
Lívia Maria do Amorim Costa GasparCenter for Studies on Colloidal Systems (NUESC)/Institute of Technology and Research (ITP), Tiradentes University (UNIT), Aracaju, Brazil.
Beatriz Benny Sungaila PereyraCenter for Studies on Colloidal Systems (NUESC)/Institute of Technology and Research (ITP), Tiradentes University (UNIT), Aracaju, Brazil.
Roberto José Meyer NascimentoInstitute of Health Science, Department of Immunology, Federal University of Bahia (UFBA), Salvador, Brazil.
Sibele BorsukTechnological Development Center, Biotechnology, Federal University of Pelotas (UFPel), Campus Universitário, Pelotas, Brazil.
Elton FranceschiCenter for Studies on Colloidal Systems (NUESC)/Institute of Technology and Research (ITP), Tiradentes University (UNIT), Aracaju, Brazil.
Francine Ferreira PadilhaCenter for Studies on Colloidal Systems (NUESC)/Institute of Technology and Research (ITP), Tiradentes University (UNIT), Aracaju, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Caseous Lymphadenitis (CLA) is a chronic disease that affects also small ruminants. CLA is caused by Corynebacterium pseudotuberculosis and is responsible for high economic losses due to the formation of superficial and visceral granulomas, the latter is considered as asymptomatic CLA causing high levels of dissemination. Several vaccination strategies, in which the use of synthetic peptides stands out. Thus, this work aimed to evaluate the protective potential of peptide vaccines designed to determine the immunodominant epitopes of CP40 against CLA in mice. The animals were divided into eight groups separated in controls (G1-PBS, G2-Saponin and G9-rCP40) and experimental (G3-pep1, G4- pep2, G5-pep3, G6-pep4, G7-pep5 and G8-pep6), these were vaccinated on days 0 and 15 by a subcutaneous route. 60 days after the first immunization, all animals were challenged with C. pseudotuberculosis. On days 0, 15, 60, and 120 after the first immunization, blood samples were taken to measure immunoglobulins. On the same day of the challenge, the splenocytes were isolated and assayed for the production of IL-2, IL-4, IL-6, IFN-γ, TNF-α, IL-17, and IL-10. After vaccinations, the animals were challenged and all of them were affected by the disease which led to their death. The G6 and G8 groups provided 10% protection and the G7 provided 20%. The G3 and G4 groups provided 30% and 40% protection respectively. The peptides showed the production of Total IgG antibodies and cytokines (IL-2, IL-4, IL-6, IFN-γ, and TNF-α), indicating a possible activation of the Th1 type response. However, groups G3, G5, G6, and G8 showed production of IL-17. None of the study groups showed IL-10 production. The immunogenicity of the peptides was not enough to protect these animals and it is believed that the use of adjuvants based on PAMPs may improve the immune response offered by these peptides.

Indexed as

Vaccine DevelopmentVaccines, SubunitAnimalsCorynebacterium InfectionsCorynebacterium pseudotuberculosisImmunity, CellularImmunity, HumoralLymphadenitisMiceVaccines, Subunit

Identifiers

PMID34843474
PMCPMC8629208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.